Abstract
Background
Patients with ulcerative colitis (UC) are at greater risk of developing colorectal cancer (CRC) than the general population. Both duration and extent of UC are important risk factors for CRC, as is the presence of primary sclerosing cholangitis, family history of CRC, and (in some studies) early age at diagnosis of UC. Efforts to reduce this risk have focused on colonoscopic surveillance as the best alternative to the more definitive, but less appealing, approach of prophylactic colectomy. However, spurred on by findings in the sporadic CRC literature, there has been a growing interest in a possible role for chemoprevention of CRC in patients with UC.
Empirical studies
Published evidence to date indicates that 5-aminosalicylic acid agents are protective against the development of dysplasia and CRC. Oral, but not topical, steroids also appear to be chemoprotective, but their chronic use cannot be recommended for this indication. Ursodeoxycholic acid has been shown to reduce the risk of neoplasia in UC patients with primary sclerosing cholangitis. Evidence suggests, but does not prove, that folic acid is chemopreventive in patients with UC. Further studies are needed to fully define the chemoprotective role of these and other agents.
Similar content being viewed by others
References
Crohn BB, Rosenberg H (1925) The sigmoidoscopic picture of chronic ulcerative colitis. Am J Med Sci 170:220–228
Gyde S, Prior P, Dew MJ, Saunders V, Waterhouse JA, Allan RN (1982) Mortality in ulcerative colitis. Gastroenterology 83:36–43
Itzkowitz SH (1997) Inflammatory bowel disease and cancer. Gastroenterol Clin North Am 26:129–139
Ransohoff DF (1988) Colon cancer in ulcerative colitis. Gastroenterology 94:1089–1091
Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:526–535
Brentnall TA, Haggitt RC, Rabinovitch PS, et al (1996) Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 110:331–338
Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA (1999) The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 94:1643–1649
Broome U, Lofberg R, Veress B, Eriksson LS (1995) Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 22:1404–1408
Loftus EV Jr, Sandborn WJ, Tremaine WJ, et al (1996) Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology 110:432–440
Gurbuz AK, Giardiello FM, Bayless TM (1995) Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Dis Colon Rectum 38:37–41
Kornfeld D, Ekbom A, Ihre T (1997) Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 41:522–525
Askling J, Dickman PW, Karlen P, et al (2001) Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 120:1356–1362
Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM (1998) Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 115:1079–1083
Bertone ER, Giovannucci EL, King NW Jr, Petto AJ, Johnson LD (1998) Family history as a risk factor for ulcerative colitis-associated colon cancer in cotton-top tamarin. Gastroenterology 114:669–674
Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB (1989) Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 97:255–259
Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323:1228–1233
Gilat T, et al (1988) Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology 94:870–877
Greenstein AJ, Sachar DB, Smith H, et al (1979) Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology 77:290–294
Sugita A, Sachar DB, Bodian C, Ribeiro MB, Aufses AH Jr, Greenstein AJ (1991) Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut 32:167–169
Collins RH Jr, Feldman M, Fordtran JS (1987) Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review. N Engl J Med 316:1654–1658
Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH (1994) Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 107:934–944
Choi PM, Nugent FW, Schoetz DJ Jr, Silverman ML, Haggitt RC (1993) Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 105:418–424
Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK, Williams CB (1990) Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 31:800–806
Provenzale D, Wong JB, Onken JE, Lipscomb J (1998) Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis. Am J Gastroenterol 93:872–880
Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson PG, Ekbom A (1998) Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 42:711–714
Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J (2000) Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 14:145–153
Giovannucci E (1999) The prevention of colorectal cancer by aspirin use. Biomed Pharmacother 53:303–308
Giovannucci E, Egan KM, Hunter DJ, et al (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609–614
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241–246
Smalley W, Ray WA, Daugherty J, Griffin MR (1999) Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 159:161–166
Giovannucci E, Stampfer MJ, Colditz GA, et al (1998) Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med 129:517–524
Giovannucci E, Stampfer MJ, Colditz GA, et al (1993) Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 85:875–884
Baron JA, Beach M, Mandel JS, et al (1999) Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 340:101–107
Giardiello FM, Hamilton SR, Krush AJ, et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316
Bansal P, Sonnenberg A (1996) Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 91:44–48
Agoff SN, Brentnall TA, Crispin DA, et al (2000) The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol 157:737–7345
Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A (1997) The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 112:29–32
Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO (1994) Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 107:117–120
Moody GA, Jayanthi V, Probert CS, MacKay H, Mayberry JF (1996) Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 8:1179–1183
Tung BY, Emond MJ, Haggitt RC, et al (2001) Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134:89–95
Bus PJ, Nagtegaal ID, Verspaget HW, et al (1999) Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 13:1397–1402
Butterworth CE Jr, Hatch KD, Gore H, Mueller H, Krumdieck CL (1982) Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. Am J Clin Nutr 35:73–82
Heimburger DC, Alexander CB, Birch R, Butterworth CE Jr, Bailey WC, Krumdieck CL (1988) Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial. JAMA 259:1525–1530
Freudenheim JL, Graham S, Marshall JR, Haughey BP, Cholewinski S, Wilkinson G (1991) Folate intake and carcinogenesis of the colon and rectum. Int J Epidemiol 20:368–374
Biasco G, Zannoni U, Paganelli GM, et al (1997) Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis. Cancer Epidemiol Biomarkers Prev 6:469–471
Hill MJ, Melville DM, Lennard-Jones JE, Neale K, Ritchie JK (1987) Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 2:185–186
Nagengast FM, Grubben MJ, van Munster IP (1995) Role of bile acids in colorectal carcinogenesis. Eur J Cancer 31A:1067–1070
Martinez JD, Stratagoules ED, LaRue JM, et al (1998) Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 31:111–118
Ochsenkuhn T, Bayerdorffer E, Meining A, et al (1999) Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 85:1664–1669
Rodrigues CM, Kren BT, Steer CJ, Setchell KD (1995) The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 109:1835–1844
Lewis JD (2001) Ursodiol prevents UC-associated CRC. Gastroenterology 121:491–492
Newmarck H, Wargovich M, Bruce W (1984) Colon cancer and dietary fat, phosphate, and calcium: a hypothesis. J Natl Cancer Inst 72:1323–1325
Pence BC, Dunn DM, Zhao C, Landers M, Wargovich MJ (1995) Chemopreventive effects of calcium but not aspirin supplementation in cholic acid-promoted colon carcinogenesis: correlation with intermediate endpoints. Carcinogenesis 16:757–765
Pence BC (1993) Role of calcium in colon cancer prevention: experimental and clinical studies. Mutat Res 290:87–95
Pence BC, Buddingh F (1988) Inhibition of dietary fat-promoted colon carcinogenesis in rats by supplemental calcium or vitamin D3. Carcinogenesis 9:187–190
Martinez ME, Willett WC (1998) Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 7:163–168
Bergsma-Kadijk J, van't Veer P, Kampman E, Burema J (1996) Calcium does not protect against colorectal neoplasia. Epidemiology 7:590–597
Holt PR, Atillasoy EO, Gilman J, et al (1998) Modulation of abnormal colonic epithelial cell proliferation and differentiation by low-fat dairy foods: a randomized controlled trial. JAMA 280:1074–1079
Rooney P, Clarke P, Gifford K-A, et al (1993) Identification of high and low risk groups of colorectal cancer using rectal mucosal crypt cell production rate (CCPR). Br J Cancer 68:172–175
Bostick RM, Boldt M, Darif M, Wood JR, Overn P, Potter JD (1997) Calcium and colorectal epithelial cell proliferation in ulcerative colitis. Cancer Epidemiol Biomarkers Prev 6:1021–1027
Acknowledgements
This research was supported in part by grants from the National Cancer Institute (RO1 CA81363) and the Chemotherapy Foundation (S.H.I.). T.A.U. is the recipient of a Career Development Award from the Crohn's and Colitis Foundation of America, and a Wilson-Cooke Award from the American Society of Gastrointestinal Endoscopy.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Croog, V.J., Ullman, T.A. & Itzkowitz, S.H. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis 18, 392–400 (2003). https://doi.org/10.1007/s00384-002-0476-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-002-0476-6